Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®
20 oct. 2017 07h30 HE
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that clinical study findings of OCR-002 (ornithine...
Ocera Therapeutics Announces Completion of Merger With Tranzyme
15 juil. 2013 12h04 HE
|
Ocera Therapeutics, Inc.
SAN DIEGO, July 15, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. ("Ocera"), a clinical stage biopharmaceutical company developing novel therapeutics for orphan liver diseases, and Tranzyme, Inc....